In this setting, endothelial dysfunction results in either low-grade secretion of tissue plasminogen activator (tPA) or enhanced plasminogen activation on the surface of the endothelial cell by urokinase or UPA (urokinase-type plasminogen activator) in subjects with Fabry disease [38]. This evidence concerns the gene PLG and Fabry disease.